Diffuse Large B-Cell

- Systemic Treatment with Curative Intent
  - VAR0174: Leveraging Mindsets to Improve Health & Wellbeing in Patients with Cancer
    - PI: Crum Stanford

- Previously Treated
  - >1 Relapse
    - MATCH Screening
      - No Mutation Match
      - Chemorefractory
        - LYMNH0122: Phase I Oral REGN1979 in CD20+ B-Cell Malignancies Previously Treated w/ CD20-Directed Antibody Therapy
          - PI: Advani Regeneron Pharmaceuticals
        - LYMNH0156: Phase I Oral SM09419 in Advanced Hematologic Malignancies
          - PI: Advani Pending
      - Not Chemorefractory
        - LYMNH0156: Phase I Oral SM09419 in Advanced Hematologic Malignancies
          - PI: Advani Pending
        - LYMNH0139: Phase Ib/Ii Hu5F9-G4 in Combo w/ Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
          - PI: Advani Forty Seven Inc.

- MATCH positive
  - ECOG-ACRIN-EAY131: Molecular Analysis for Therapy Choice (MATCH)
    - PI: Ford ECOG-ACRIN

KEY
- Pending
- Open for Enrollment
- Link
- Trial Posting
- Optional Path
- Extension Study
- Immunotherapy